期刊
BREAST CANCER RESEARCH
卷 13, 期 6, 页码 -出版社
BMC
DOI: 10.1186/bcr2912
关键词
-
类别
资金
- Novartis Pharmaceuticals, Inc.
- NATIONAL CANCER INSTITUTE [F32CA156991] Funding Source: NIH RePORTER
Breast cancer comprises a heterogeneous group of malignancies derived from the ductal epithelium. The microenvironment of these cancers is now recognized as a critical participant in tumor progression and therapeutic responses. Recent data demonstrate significant gene expression and epigenetic alterations in cells composing the microenvironment during disease progression, which can be explored as biomarkers and targets for therapy. Indeed, gene expression signatures derived from tumor stroma have been linked to clinical outcomes. There is increasing interest in translating our current understanding of the tumor microenvironment to the development of novel therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据